Enterprise Value
373.7M
Cash
383.5M
Avg Qtr Burn
-2.562M
Short % of Float
1.38%
Insider Ownership
6.54%
Institutional Own.
69.91%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Obicetrapib Details Heterozygous familial hypercholesterolemia, Atherosclerotic cardiovascular disease | Phase 3 Data readout | |
Obicetrapib + ezetimibe Details Dyslipidemia, Hypercholesterolemia | Phase 3 Initiation | |
Obicetrapib Details Dyslipidemia | Phase 2b Update | |
Obicetrapib Details Alzheimer's disease | Phase 2a Data readout |